Table 1.
Summary of literature reports including: diagnosis, tumor markers, immunohistochemistry, hormone receptors, treatment, recurrence/metastasis, and surveillance.
| Author | Diagnosis | Tumor marker | Immunohistochemical markers | Hormone receptors | Treatment | Recurrence/Metastasis | Surveillance |
|---|---|---|---|---|---|---|---|
| Rosen et al., 2019 | Benign FATWO (incidental) | NA | inhibin, calretinin, pancytokeratin, and CD10 (+) | ER/PR (−) | Pelvic wall mass removal ONLY | NA | 1 month follow up |
| PAX-8, CD34, actin, desmin, S100, EMA, and HMB45 (−) | |||||||
| Ramirez et al., 2002 | FATWO with 3 yr recurrence | Elevated CA-125 = 286 > 46 (recurrence) | inhibin, calretinin, and focally for cytokeratin 7 (+) | PR (+) | Ex lap and tumor reductive surgery – BSO, omenectomy, perihepatic mass excision | First − 3 y post op | NA |
| Case 1 | epithelial membrane antigen (EMA) (−) | ER, c-kit and Her2/neu (−) | carboplatinum/paclitaxel, leuprolide – progressive disease | Second − 4 mos after excision of secondary | |||
| Case 2 | Recurrent FATWO | CA-125 = 13 | calretinin, cytokeratin, and Moc31 (+) | ER/PR (+) | Exploratory laparotomy, omentectomy, and tumor reductive surgery | New nodules in LU pelvis | 10 and 17 months |
| CEA = 1.5 | focally positive for CK5/6. | c-Kit and Her-2/neu (−) | |||||
| negative for inhibin, B72.3, CK20, S-100 protein, EMA, and p53. | |||||||
| Sheyn et al., 2000 | Metastatic FATWO | CA-125 wnl | cytokeratin CAM5.2 and vimentin (+) | NA | TAH, BSO, omentectomy, low anterior resection of rectosigmoid with primary anastomosis, and appendectomy | Recurrence 5 years | followed up by serial CT, chest x-ray films, and cancer antigen 125 levels every 6 months. |
| EMA, S100, and a-inhibin (−) | cysplatin-cytoxan chemotherapy | ||||||
| Hong et al., 2017 | Malignant FATWO | CA-125 = 70.3 | CD10, CK7, and EMA (+) | ER/PR (+) | TAH, BSO mass resection, omentectomy, and left iliac and paraaortic lymphadenectomy. | NA | “close monitoring” |
| HE4 = 147 CEA = 4.3 | CEA, inhibin, CD99, Calretinin, CK20, WT-1, and PAX8 (−) | ||||||
| Syriac et al., 2011 | Recurrent FATWO | NA | C-kit (CD117), AE1/3, cytokeratin (CK)7, WT1, calretinin, and α-inhibin (+) | NA | TAH, BSO, omentectomy and bilateral pelvic and para-aortic lymph node dissection | 3 year recurrence | follow-up by CT every 6 months |
| EMA) CK20, and synaptophysin (−) | Imatinib mesylate therapy for 6 months | ||||||
| Hubner et al., 2019 | Benign FATWO | Ca-125 = 23.1 | CD10 and cytokeratins (the pancytokeratin antibodies AE1/3, Cam5.2, cytokeratin 7) | PR (+) | laparoscopic tumor removal and chromopertubation. | NA | NA |
| CEA = 0.3 | Inhibin (+) | ER (−) | |||||
| irregular, diffuse reactivity for SF1 partial positivity for calretinin and CD56. | |||||||
| FOXL2 (−) | |||||||
| Bennett et al., 2020 | 15 cases | NA | Pankeratin, EMA,GATA3, and PAX8 (+) | NA | NA | 1 patient with recurrence | 6 patients followed ranging 1 to 14 years |
| Review of 15 cases | Mostly benign FATWOs | TTF-1 (−) | |||||
| CD10, SF-1, calretinin, inhibin, ER/PR, cytokeratin 7, and WT1 variably expressed. |